Influenza A virus A/Singapore/GP1908/2015 IVR-180A (H1N1) antigen (propiolactone inactivated)

DB14468ApprovedWithdrawnVaccines

A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection... Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen".

First approval: United States, 2011

Resolves to

Compound

UNII9JWN7VDQ7N

Clinical / RWD

RxNorm1928290

What you can answer from here — as of April 02, 2025

2Clinical trialsPhase, status and sponsor resolved per trial

1Structured indicationCondition, population, route and combination as fields, not prose

8Marketed productsAcross 1 country and 1 labeller

Which other approved drugs treat the same conditions as Influenza A virus A/Singapore/GP1908/2015 IVR-180A (H1N1) antigen (propiolactone inactivated), and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account